sod1 (Proteintech)
Structured Review

Sod1, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 401 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/sod1/product/Proteintech
Average 96 stars, based on 401 article reviews
Images
1) Product Images from "The sphingolipid metabolite sphingosine protects against hypertension by targeting metabolic-inflammatory crosstalk via the NLRP3 inflammasome"
Article Title: The sphingolipid metabolite sphingosine protects against hypertension by targeting metabolic-inflammatory crosstalk via the NLRP3 inflammasome
Journal: International Journal of Cardiology. Cardiovascular Risk and Prevention
doi: 10.1016/j.ijcrp.2025.200562
Figure Legend Snippet: SPH regulates NLRP3 inflammasome, ER stress, oxidative stress, and apoptosis/survival pathways in the hearts of hypertensive mice. (A, B) Representative Western blots and densitometric analysis for ER stress (GRP78), NLRP3 inflammasome components (NLRP3, ASC, C-Caspase-1, C-IL-1β, C-GSDMD), and oxidative stress (SOD1). (C–H) Relative mRNA expression of Nlrp3, Asc, Casp1, Gsdmd, IL1b, and IL18 by qRT-PCR. (I, J) Representative Western blots and densitometric analysis for apoptosis markers (BAX, BCL2, C-Caspase-3) and PI3K/AKT pathway proteins (p-PI3K, PI3K, p-AKT, AKT). GAPDH or total proteins were used for normalization. Data are mean ± SEM (n = 3 per group). Statistical analysis was by one-way ANOVA with Tukey's post-hoc test.
Techniques Used: Western Blot, Expressing, Quantitative RT-PCR
Figure Legend Snippet: SPH protects human umbilical vein endothelial cells (HUVECs) from Angiotensin IIinduced injury, pyroptosis, and oxidative stress by inhibiting the NLRP3 inflammasome pathway. (A) Cell viability of HUVECs treated with AngII (1 μM) for 12 h followed by various concentrations of SPH (0.5–6 μM) for 24 h. (B) Cell viability of HUVECs treated with SPH alone for 24 h. (C, D) Representative Western blots and densitometric analysis for NLRP3 inflammasome components (NLRP3, ASC, c-Caspase-1, c-IL-1β), the pyroptosis effector N-GSDMD, ER stress marker GRP78, and oxidative stress marker SOD1. (E–J) Relative mRNA expression of NLRP3, ASC, CASP1, IL1B, IL18, and GSDMD by RT-qPCR. Data are the mean ± SEM of three independent experiments. ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001, ∗∗∗∗P < 0.0001 vs. the AngII-only group, unless otherwise indicated.
Techniques Used: Western Blot, Marker, Expressing, Quantitative RT-PCR
Figure Legend Snippet: SPH mitigates Angiotensin II-induced inflammasome activation, apoptosis, and oxidative stress in HUVECs. (A, B) Representative immunofluorescence images showing increased expression of NLRP3 (red, A) and ASC (green, B) in AngII-treated cells, which is reduced by subsequent SPH treatment. Scale bar = 100 μm. (C) TUNEL assay (green) demonstrating increased apoptosis in AngII-treated cells, which is attenuated by SPH. Scale bar = 100 μm. (D, E) Biochemical assays showing that SPH or MCC950 treatment reverses the AngII-induced decrease in SOD1 activity (G).NO (H) and increase in MDA levels (D). (F, G) DCFH-DA staining showing increased intracellular ROS (green) after AngII treatment, which is suppressed by SPH or MCC950. Representative images (F) and quantification (E) are shown. (I, J) ELISA results showing that SPH or MCC950 treatment inhibits the AngII-induced secretion of IL-1β (I) and IL-18 (J). (K) Scanning electron microscopy (SEM) images showing that SPH or MCC950 treatment improves the cell surface morphology and reduces features of pyroptotic damage induced by AngII. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)
Techniques Used: Activation Assay, Immunofluorescence, Expressing, TUNEL Assay, Activity Assay, Staining, Enzyme-linked Immunosorbent Assay, Electron Microscopy
